« Previous
Next »
Thrombosis Research
Volume 122
, Pages S9-S15
, 2008
Pre-clinical studies of plasmin: Superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator
References
- Clinical pharmacology of various types of fibrinolytic enzyme preparations. Am J Cardiol. 1960;6:462–475
- . Thrombolytic therapy. Br Med Bull. 1964;20:228–232
- . A proteolytic enzyme of serum: characterization, activation and reaction with inhibitors. J Gen Physiol. 1945;28:559–583
- . Mechanisms of fibrinolysis. In: Williams WJ, Beutler E, Erslev AJ, Rundles RW editor. Hematology. New York: McGraw-Hill; 1977;p. 1297;Section 7, Chapter 4
- . Thrombolytic therapy: current status (1). N Engl J Med. 1988;318:1512–1520
- . Thrombolytic therapy: current status (2). N Engl J Med. 1988;318:1585–1595
- . The use of thrombolytic agents: choice of patient, drug administration, laboratory monitoring. Ann Intern Med. 1979;90:802–808
- Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost. 2001;86:739–745
- . On the regulation and control of fibrinolysis. Thromb Haemost. 1980;43:77–89
- . Distinct dose-dependent effects of plasmin and TPA on coagulation and hemorrhage. Blood. 2003;101:3002–3007
- . Clinical risks of thrombolytic therapy. Am J Cardiol. 1992;69:12A–20A
- Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis. Stroke. 2008;39:1613–1615
☆ Supported by Grant RO1 HL 074051 from the National Heart Lung and Blood Institute, NIH, Bethesda, MD, and by a grant from Talecris BioTherapeutics, RTP, NC.
PII: S0049-3848(08)00239-9
doi: 10.1016/j.thromres.2008.06.019
© 2008 Elsevier Ltd. All rights reserved.
« Previous
Next »
Thrombosis Research
Volume 122
, Pages S9-S15
, 2008
